133 related articles for article (PubMed ID: 11029531)
21. Immunohistochemical detection of adhesion molecule CD44 splice variants in lymph node metastases of cervical cancer.
Kainz C; Tempfer C; Kohlberger P; Janisch S; Koelbl H; Gitsch G; Breitenecker G
Int J Cancer; 1996 Jun; 69(3):170-3. PubMed ID: 8682582
[TBL] [Abstract][Full Text] [Related]
22. Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases.
Schröder W; Rudlowski C; Biesterfeld S; Knobloch C; Hauptmann S; Rath W
Anticancer Res; 1999; 19(5B):3901-6. PubMed ID: 10628329
[TBL] [Abstract][Full Text] [Related]
23. The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies.
Porcel JM; Esquerda A; Rodriguez-Panadero F; Martínez-Iribarren A; Bielsa S
J Thorac Oncol; 2011 Jan; 6(1):190-4. PubMed ID: 21079519
[TBL] [Abstract][Full Text] [Related]
24. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
[TBL] [Abstract][Full Text] [Related]
25. Significant elevation of tumour-associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking.
Kittl EM; Ruckser R; Rech-Weichselbraun I; Hinterberger W; Bauer K
Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):81-4. PubMed ID: 9056747
[TBL] [Abstract][Full Text] [Related]
26. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
27. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
Sosulski A; Horn H; Zhang L; Coletti C; Vathipadiekal V; Castro CM; Birrer MJ; Nagano O; Saya H; Lage K; Donahoe PK; Pépin D
PLoS One; 2016; 11(6):e0156595. PubMed ID: 27253518
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of serum levels of CD44 variant exons 8-10 protein in colorectal cancer.
Yamaguchi A; Goi T; Taguchi S; Ohtaki N; Seki K; Hirose K; Nakagawara G; Urano T; Furukawa K
J Gastroenterol; 1998 Jun; 33(3):349-53. PubMed ID: 9658313
[TBL] [Abstract][Full Text] [Related]
29. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
30. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia.
De Rossi G; Marroni P; Paganuzzi M; Mauro FR; Tenca C; Zarcone D; Velardi A; Molica S; Grossi CE
Leukemia; 1997 Jan; 11(1):134-41. PubMed ID: 9001429
[TBL] [Abstract][Full Text] [Related]
31. Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
Shi J; Zhou Z; Di W; Li N
BMC Cancer; 2013 Apr; 13():182. PubMed ID: 23565736
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis.
Amirghofran Z; Jalali SA; Hosseini SV; Vasei M; Sabayan B; Ghaderi A
J Gastrointest Cancer; 2008; 39(1-4):73-8. PubMed ID: 19333790
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of elevated serum CD44 levels in patients with oral squamous cell carcinoma.
Sawant S; Ahire C; Dongre H; Joshi S; Jamghare S; Rane P; Kane S; Chaukar D
J Oral Pathol Med; 2018 Aug; 47(7):665-673. PubMed ID: 29752852
[TBL] [Abstract][Full Text] [Related]
34. Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies.
Taylor DD; Gercel-Taylor C; Gall SA
J Soc Gynecol Investig; 1996; 3(5):289-94. PubMed ID: 8796842
[TBL] [Abstract][Full Text] [Related]
35. Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumours of the ovary.
Daraï E; Bringuier AF; Walker-Combrouze F; Feldmann G; Madelenat P; Scoazec JY
Hum Reprod; 1998 Oct; 13(1O):2831-5. PubMed ID: 9804241
[TBL] [Abstract][Full Text] [Related]
36. Serum CD44 splice variants in cervical cancer patients.
Kainz C; Tempfer C; Winkler S; Sliutz G; Koelbl H; Reinthaller A
Cancer Lett; 1995 Apr; 90(2):231-4. PubMed ID: 7537626
[TBL] [Abstract][Full Text] [Related]
37. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas.
Afify AM; Ferguson AW; Davila RM; Werness BA
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):309-14. PubMed ID: 11759056
[TBL] [Abstract][Full Text] [Related]
38. The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.
Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Fanucchi A; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1998; 18(1B):537-9. PubMed ID: 9568174
[TBL] [Abstract][Full Text] [Related]
39. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
40. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
